Key facts
- RegCell’s last known valuation is $17.9M (Apr 2022).
- It has raised $63.9M; the latest was Later Stage VC ($45.8M) in Mar 2025.
- Notable investors include Mitsubishi UFJ Capital, Global Brain, J-Startup, Nissay Capital, Japan External Trade Organization — 24 tracked in total.
- Status: Privately Held (backing).
Investors
24+- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for RegCell
- ·The full record, as it builds
Funding rounds
No funding rounds for RegCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RegCell
Developer of autoimmune drugs intended to provide medical care for autoimmune diseases and cancer. The company utilizes a research protocol that involves regulating control T cells to proliferate and activate them outside the body and then return them to patients, enabling patients to avail an effective treatment method for autoimmune diseases.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2016
- Employees
- 7
- Website
- regcellbio.com/
- Ownership
- Privately Held (backing)
RegCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RegCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RegCell in its N-PORT filings yet. We sweep new filings monthly.